Structure Therapeutics Inc. Maintains Bullish Momentum as Institutions Reshape Positions

Analyst Confidence Remains Strong with 15.38% Upside Potential

Citizens reaffirmed its bullish stance on Structure Therapeutics Inc. - Depositary Receipt (GPCR) as of December 12, 2025, maintaining a Market Outperform rating on the stock. Market consensus paints an optimistic picture, with analysts projecting a one-year price target of $77.37 per share as of December 6, 2025—representing a 15.38% upside from the latest closing price of $67.06. Price projections span a wide range, from a conservative $50.50 to an ambitious $126.00, reflecting varying degrees of confidence in the GPCR growth narrative.

Financial Projections Signal Mixed Signals

Looking ahead, Structure Therapeutics Inc. is expected to generate approximately $51 million in annual revenue, though profitability remains a question mark with a projected non-GAAP EPS of -0.69. This loss-making status is not uncommon for biotech and therapeutics companies in growth phases, where investment in research and development often takes precedence over near-term profitability.

Institutional Interest Shifts Dramatically

The broader investor base for GPCR comprises 269 funds and institutions, though this represents a notable decline of 31 positions (10.33%) from the previous quarter. Despite the reduction in investor count, the average portfolio allocation has ticked upward by 11.14%, suggesting that remaining investors are doubling down on their conviction. Interestingly, total institutional ownership dipped 0.31% to 66.389 million shares over three months, signaling cautious optimism rather than exuberant accumulation.

Market sentiment leans bullish, as evidenced by the put/call ratio of 0.60, which indicates investors are more inclined toward calls than puts—a sign of constructive positioning.

Major Players Recalibrate Holdings

Wellington Management Group Llp, one of the largest holders with 5.689 million shares, has trimmed its position by 20.86% compared to its prior filing (down from 6.876 million shares). However, the firm paradoxically increased its portfolio allocation by 7.73%, suggesting a strategic rebalancing rather than a loss of faith in GPCR.

Avoro Capital Advisors made a significant entrance into the GPCR story, acquiring 5.156 million shares from a zero position—a 100% increase that signals fresh institutional interest. Meanwhile, Janus Henderson Group holds 4.449 million shares, though this represents a 2.79% reduction from its prior 4.573 million shares. The firm also substantially decreased its portfolio weighting by 52.90%, hinting at a shift in strategy.

Deep Track Capital maintains a substantial 4.216-million-share position, down 21.78% from 5.134 million shares previously held. Similarly, its portfolio allocation declined by 3.53%, suggesting modest disengagement. Bvf, however, demonstrates renewed enthusiasm with 3.204 million shares—a 44.71% jump from 1.771 million shares held before. This aggressive 177.06% increase in portfolio allocation underscores renewed confidence in GPCR’s near-term prospects.

The Bottom Line

Structure Therapeutics Inc. continues to attract analyst support and institutional interest, despite some profit-taking and position adjustments among major funds. The 15.38% upside potential outlined by consensus forecasts presents an intriguing opportunity for investors comfortable with the biotech sector’s inherent volatility and the company’s loss-making status. With mixed signals from institutional moves—some reducing exposure while others aggressively buying—the market remains divided on whether current valuations offer fair entry points or warning signs of a potential pullback.